Annual report [Section 13 and 15(d), not S-K Item 405]

Consolidated Statements of Changes in Redeemable Non-controlling Interests and Stockholders' Equity

v3.25.0.1
Consolidated Statements of Changes in Redeemable Non-controlling Interests and Stockholders' Equity - USD ($)
$ in Thousands
Total
Additional Paid-in Capital
Retained Earnings
Treasury Stock
Accumulated Other Comprehensive Loss
Non-controlling Interest (“NCI”)
Class A Common Stock
Class A Common Stock
Common Stock
Class B Common Stock
Class B Common Stock
Common Stock
Redeemable non-controlling interests beginning balance at Dec. 31, 2021 $ 46,182                  
Increase (Decrease) in Temporary Equity [Roll Forward]                    
Distributions to RNCI (1,039)                  
Accretion of tax equity financing fees 109                  
Investment fund call option exercise (2,162)                  
Net income 3,533                  
Redeemable non-controlling interests ending balance at Dec. 31, 2022 46,623                  
Beginning balance (in shares) at Dec. 31, 2021               33,716,309   18,000,000
Treasury stock, beginning balance (in shares) at Dec. 31, 2021       2,101,795            
Beginning balance at Dec. 31, 2021 704,264 $ 283,982 $ 438,732 $ (11,788) $ (6,667) $ 0   $ 3   $ 2
Increase (Decrease) in Stockholders' Equity [Roll Forward]                    
Exercise of stock options (in shares)               195,888    
Exercise of stock options 3,954 3,954                
Stock-based compensation expense 15,046 15,046                
Employee stock purchase plan (in shares)               36,165    
Employee stock purchase plan 2,009 2,009                
Unrealized gain (loss) from interest rate hedges, net 6,017       6,017          
Foreign currency translation adjustment (3,401)       (3,401)          
Accretion of tax equity financing fees (109)   (109)              
Investment fund call option exercise 1,323 1,323                
Contributions from NCI 48,912         48,912        
Net income 95,016   94,926     90        
Ending balance (in shares) at Dec. 31, 2022               33,948,362   18,000,000
Treasury stock, ending balance (in shares) at Dec. 31, 2022       2,101,795            
Ending balance at Dec. 31, 2022 873,031 306,314 533,549 $ (11,788) (4,051) 49,002   $ 3   $ 2
Increase (Decrease) in Temporary Equity [Roll Forward]                    
Distributions to RNCI (632)                  
Accretion of tax equity financing fees 108                  
Investment fund call option exercise 195                  
Net income 571                  
Redeemable non-controlling interests ending balance at Dec. 31, 2023 46,865                  
Increase (Decrease) in Stockholders' Equity [Roll Forward]                    
Exercise of stock options (in shares)               246,250    
Exercise of stock options 2,438 2,438                
Stock-based compensation expense 10,318 10,318                
Employee stock purchase plan (in shares)               60,003    
Employee stock purchase plan 2,017 2,017                
Restricted stock units released (in shares)               22,580    
Unrealized gain (loss) from interest rate hedges, net (538)       (538)          
Foreign currency translation adjustment 1,574       1,544 30        
Accretion of tax equity financing fees (108)   (108)              
Investment fund call option exercise (195) (195)                
Contributions from NCI 4,203         4,203        
Distributions to NCI (30,187)         (30,187)        
Net income $ 63,333   62,470     863        
Ending balance (in shares) at Dec. 31, 2023             34,277,195 34,277,195 18,000,000 18,000,000
Treasury stock, ending balance (in shares) at Dec. 31, 2023 2,101,795     2,101,795            
Ending balance at Dec. 31, 2023 $ 925,886 320,892 595,911 $ (11,788) (3,045) 23,911   $ 3   $ 2
Increase (Decrease) in Temporary Equity [Roll Forward]                    
Distributions to RNCI (288)                  
Accretion of tax equity financing fees 107                  
Investment fund call option exercise (40,455)                  
Net income (3,766)                  
Redeemable non-controlling interests ending balance at Dec. 31, 2024 $ 2,463                  
Increase (Decrease) in Stockholders' Equity [Roll Forward]                    
Exercise of stock options (in shares) 97,000             97,489    
Exercise of stock options $ 942 942                
Stock-based compensation expense 14,130 14,130                
Employee stock purchase plan (in shares)               63,903    
Employee stock purchase plan 1,821 1,821                
Restricted stock units released (in shares)               62,626    
Restricted stock units released       40            
Unrealized gain (loss) from interest rate hedges, net 394       394          
Foreign currency translation adjustment (3,172)       (3,223) 51        
Accretion of tax equity financing fees (107)   (107)              
Investment fund call option exercise 37,269 37,269                
Contributions from NCI 35,407 3,040       32,367        
Distributions to NCI (1,368)         (1,368)        
Purchase of shares from NCI (23,759) 227       (23,986)        
Net income $ 57,706   56,757     949        
Ending balance (in shares) at Dec. 31, 2024             34,501,213 34,501,213 18,000,000 18,000,000
Treasury stock, ending balance (in shares) at Dec. 31, 2024 2,101,835     2,101,835            
Ending balance at Dec. 31, 2024 $ 1,045,149 $ 378,321 $ 652,561 $ (11,788) $ (5,874) $ 31,924   $ 3   $ 2